(Q51159286)

31 March 2018

title

Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. (English)

1 reference

31 March 2018

chronic obstructive pulmonary disease

main subject

1 reference

Jørgen Vestbo

1

0 references

William MacNee

object named as

William MacNee

12

0 references

Ruth Tal-Singer

17

object named as

Ruth Tal-Singer

1 reference

31 March 2018

3

Emiel F M Wouters

1 reference

31 March 2018

author name string

Alvar Agusti

2

1 reference

31 March 2018

Per Bakke

4

1 reference

31 March 2018

Peter M A Calverley

5

1 reference

31 March 2018

Bartolome Celli

6

1 reference

31 March 2018

Harvey Coxson

7

1 reference

31 March 2018

Courtney Crim

8

1 reference

31 March 2018

Lisa D Edwards

9

1 reference

31 March 2018

Nicholas Locantore

10

1 reference

31 March 2018

David A Lomas

11

1 reference

31 March 2018

Bruce Miller

13

1 reference

31 March 2018

Stephen I Rennard

14

1 reference

31 March 2018

Edwin K Silverman

15

1 reference

31 March 2018

Julie C Yates

16

1 reference

31 March 2018

Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Study Investigators

18

1 reference

31 March 2018

language of work or name

English

0 references

publication date

1 May 2014

1 reference

31 March 2018

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

31 March 2018

volume

189

1 reference

31 March 2018

issue

9

1 reference

31 March 2018

page(s)

1022-1030

1 reference

31 March 2018

The natural history of chronic airflow obstruction

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

COPD, a multicomponent disease: implications for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Characterisation of COPD heterogeneity in the ECLIPSE cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Changes in forced expiratory volume in 1 second over time in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Chronic obstructive pulmonary disease phenotypes: the future of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Frequent chronic obstructive pulmonary disease exacerbators: how much real, how much fictitious?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Pulmonary emphysema: objective quantification at multi-detector row CT--comparison with macroscopic and microscopic morphometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

CT-quantified emphysema in male heavy smokers: association with lung function decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Factors influencing the decline in lung density in a Danish lung cancer screening cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Bronchodilator response in the lung health study over 11 yrs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Bronchodilator reversibility testing in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Club cell protein 16 and disease progression in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

COPD association and repeatability of blood biomarkers in the ECLIPSE cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

The COPD Biomarker Qualification Consortium (CBQC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Chronic Obstructive Pulmonary Disease Biomarker(s) for Disease Activity Needed—Urgently

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Determinants of poor 6-min walking distance in patients with COPD: The ECLIPSE cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

Complex chronic comorbidities of COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201311-2006PP

10.1164/RCCM.201311-2006PP

21 January 2018

Identifiers

DOI

1 reference

31 March 2018

PubMed ID

24552242

1 reference

31 March 2018